Purple Biotech Ltd
TASE:PPBT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Purple Biotech Ltd
Income from Continuing Operations
Purple Biotech Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Purple Biotech Ltd
TASE:PPBT
|
Income from Continuing Operations
-$26.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-20%
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Income from Continuing Operations
$1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-2%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Income from Continuing Operations
-$6.1m
|
CAGR 3-Years
26%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Income from Continuing Operations
-$34.2m
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Income from Continuing Operations
-$23.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-1%
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Income from Continuing Operations
-₪18.1m
|
CAGR 3-Years
-107%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Purple Biotech Ltd
Glance View
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
See Also
What is Purple Biotech Ltd's Income from Continuing Operations?
Income from Continuing Operations
-26.5m
USD
Based on the financial report for Dec 31, 2025, Purple Biotech Ltd's Income from Continuing Operations amounts to -26.5m USD.
What is Purple Biotech Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-20%
Over the last year, the Income from Continuing Operations growth was -264%. The average annual Income from Continuing Operations growth rates for Purple Biotech Ltd have been -7% over the past three years , 2% over the past five years , and -20% over the past ten years .
